Avidity NanoMedicines is pioneering a new class of therapeutics, antibody-siRNA complexes (ARCs™), which employ antibody-targeted nanoparticles containing siRNA payloads. The technology draws on the targeting associated with antibody-drug conjugates and the selectivity of nucleic acid-based medicines. Through partnerships with academic and industry experts, Avidity is applying its technology to the discovery and development of novel, targeted drugs. Founded in 2013, the company entered into a research and development collaboration with a major pharmaceutical company in December 2013 and completed a $9 million Series A financing in January 2014. Avidity NanoMedicines is a privately held company located in La Jolla, California.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/08/14 | $6,000,000 | Convertible Debt |
Alethea Capital Management Brace Pharma Partner Fund Management TPG Biotech | undisclosed |
